No.23-22

March 24, 2023
Eisai Co., Ltd.

EISAI TO PRESENT RESEARCH FROM ONCOLOGY PORTFOLIO AT THE SOCIETY OF
GYNECOLOGIC ONCOLOGY (SGO) 2023 ANNUAL MEETING ON WOMEN’S CANCER
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today the presentation of two
abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer(#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.
Notable research to be featured in the Scientific Plenary IX: The Best of the Rest session includes apresentation of real-world outcomes and healthcare resource utilization in patients with recurrent oradvanced endometrial carcinoma who were rechallenged with platinum chemotherapy in Europe (Abstract:#17). Also to be presented are data from the LEAP (LEnvatinib And Pembrolizumab) clinical program
analyzing tumor-response from the lenvatinib (LENVIMA®) plus pembrolizumab (KEYTRUDA®) arm of thepivotal Phase 3 Study 309/KEYNOTE-775 trial in patients with advanced endometrial carcinoma following
at-least one prior platinum-based regimen in any setting (NCT03517449; Abstract: #518).
“We look forward to sharing our data at this year’s SGO Annual Meeting, particularly a new study that will
be presented in an oral scientific plenary session featuring real-world outcomes in patients with recurrent
or advanced endometrial cancer who were rechallenged with platinum chemotherapy,” said Dr. Takashi
Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. “We believe this research is importantto the healthcare providers and patients we aim to serve because it is essential to understand treatmentdynamics and related outcomes in clinical practice. As a human health care company, we remain steadfast
in our commitment to advance the science of cancer medicine through the generation of real-worldevidence.”
In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the UnitedStates and Canada), through an affiliate, entered into a strategic collaboration for the worldwide codevelopment and co-commercialization of lenvatinib, both as monotherapy and in combination withMerck’s anti-PD-1 therapy pembrolizumab. To date, more than 10 trials have been initiated under theLEAP clinical program, which is evaluating the combination across multiple tumor types.
This release discusses investigational compounds and investigational uses for FDA-approved products. It
is not intended to convey conclusions about efficacy and safety. There is no guarantee that any
investigational compounds or investigational uses of FDA-approved products will successfully complete
clinical development or gain FDA approval.

The full list of Eisai presentations is included below. Full abstracts will be posted the day of scheduled
presentations.
Study/CompoundAbstract Title

Abstract Type & Details(Eastern Daylight Time)

Real World Evidence
Endometrial Cancer NonInterventional Study

Real-world outcomes and healthcare
resource utilization in recurrent oradvanced endometrial cancer patientsrechallenged with platinum
chemotherapy in Europe

Oral Scientific Plenary
Abstract #17
March 28, 2023
10:30-11:45 AM

Characterization of tumor responsewith lenvatinib plus pembrolizumab inStudy 309/KEYNOTE-775

Poster Discussion
Abstract #518
March 27, 2023
10:40-11:20 AM

LEAP clinical program
Study 309/KEYNOTE-775

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120[Notes to editors]
1. Eisai’s Focus on Cancer
Eisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery anddevelopment of anti-cancer drugs within drug discovery domains including “tumor microenvironment”, “proteostasisdisruption”, “cell linage and cell differentiation”, and “inflammation, hypoxia, oxidative stress and cell senescence”
under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires todiscover innovative new drugs with new targets and mechanisms of action from these domains with the aim ofcontributing to the cure of cancers.
* KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC., a subsidiary of Merck & Co., Inc., Rahway,
NJ, USA.

###